Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Mylan Japan Offers Severance Package for 110 Sales Reps
A Japan arm of major generic maker Mylan, Mylan Seiyaku, is offering a severance package for some 110 sales reps who will return from Pfizer Japan, the company’s partner in the generic business in the country, at the end of…
To read the full story
Related Article
- Mylan Japan Labor Union, Management Reach Settlement; All 14 Members to Leave on May 31
May 30, 2016
- Mylan Japan Management, Labor Union Remain at Odds over Sales Rep Layoff
April 21, 2016
- Mylan Japan Labor Union Raps Management over “Effective Dismissal”, No Progress Made in 1st Round of Negotiations
April 6, 2016
- Japan Units of Abbott, Mylan to Run Separate Operations for Now
March 4, 2015
- All Eyes Glued to Japan Realignment after Mylan’s Buyout of Abbott’s Established Product Biz
September 8, 2014
- Mylan Generics Will Be Distributed under Pfizer Brand Next Year: Pfizer’s Matsumori
July 17, 2013
- Pfizer-Mylan Pair’s Japan Generic Share at 2.8%, Aspire for Bigger Slice of Market
April 22, 2013
- Pfizer Confident about Joining Top 3 in Japan Generic Sales by around 2015: Unit Chief Matsumori
February 7, 2013
- Pfizer, Mylan Ink Strategic Collaboration in Japan Generics Biz; Aim for No. 3 in Market
August 24, 2012
BUSINESS
- Ferring’s Adstiladrin, Boehringer’s Jascayd Hit Market; Haizexin Due July 28
July 16, 2026
- Nipro Pharma Recalls Topical Drugs over Long-Running Manufacturing Deviations
July 16, 2026
- JCR to File DMD Drug Givinostat in Japan by End-2026
July 16, 2026
- Daiichi Sankyo Healthcare to Take Over Claritin EX Sales in Japan
July 16, 2026
- Maruishi Set to Secure Japan Rights to Kringle’s Vocal Fold Scar Drug
July 16, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…